MA33059B1 - Utilisation d'antagonistes des recepteurs nk - Google Patents

Utilisation d'antagonistes des recepteurs nk

Info

Publication number
MA33059B1
MA33059B1 MA34113A MA34113A MA33059B1 MA 33059 B1 MA33059 B1 MA 33059B1 MA 34113 A MA34113 A MA 34113A MA 34113 A MA34113 A MA 34113A MA 33059 B1 MA33059 B1 MA 33059B1
Authority
MA
Morocco
Prior art keywords
antagonists
receptors
itching
hydrate
solvent
Prior art date
Application number
MA34113A
Other languages
Arabic (ar)
English (en)
Inventor
Anton Stuetz
Barbara Wolff-Winiski
Lina Williamson
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42102184&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33059(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA33059B1 publication Critical patent/MA33059B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne l'utilisation d'un composé de formule (I) ou d'un solvate ou hydrate de celui-ci, dont les constituants sont tels que définis dans la description, et de combinaisons de ceux-ci, pour traiter le prurit ou autre désordre ou maladie dermatologique.
MA34113A 2009-02-24 2010-02-23 Utilisation d'antagonistes des recepteurs nk MA33059B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15497309P 2009-02-24 2009-02-24
PCT/EP2010/052273 WO2010097381A1 (fr) 2009-02-24 2010-02-23 Utilisations d'antagonistes des récepteurs nk

Publications (1)

Publication Number Publication Date
MA33059B1 true MA33059B1 (fr) 2012-02-01

Family

ID=42102184

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34113A MA33059B1 (fr) 2009-02-24 2010-02-23 Utilisation d'antagonistes des recepteurs nk

Country Status (17)

Country Link
US (1) US20120077803A1 (fr)
EP (1) EP2400953A1 (fr)
JP (1) JP5425229B2 (fr)
KR (1) KR20110118830A (fr)
CN (1) CN102395358A (fr)
AU (1) AU2010217615C1 (fr)
BR (1) BRPI1008008A2 (fr)
CA (1) CA2753330A1 (fr)
CL (1) CL2011002045A1 (fr)
EA (1) EA201101207A1 (fr)
IL (1) IL214731A0 (fr)
MA (1) MA33059B1 (fr)
MX (1) MX2011008878A (fr)
SG (1) SG173758A1 (fr)
TN (1) TN2011000428A1 (fr)
TW (1) TW201034674A (fr)
WO (1) WO2010097381A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE046508T2 (hu) * 2012-10-11 2020-03-30 Nerre Therapeutics Ltd Orvepitant krónikus viszketés kezelésére
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8987289B2 (en) * 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
KR20190039936A (ko) * 2016-06-29 2019-04-16 멘로 쎄라퓨틱스 인크. 다양한 소양증성 병태를 치료하기 위한 뉴로키닌-1 길항제의 용도
MX2021000908A (es) 2018-07-23 2021-06-08 Trevi Therapeutics Inc Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.
MX2022008554A (es) 2020-01-10 2022-08-10 Trevi Therapeutics Inc Metodos de administracion de nalbufina.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2728166A1 (fr) * 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2740040B1 (fr) * 1995-10-23 1997-12-05 Oreal Utilisation d'au moins un agoniste beta-adrenergique en tant qu'antagoniste de substance p
DE19541283A1 (de) * 1995-11-06 1997-05-07 Boehringer Ingelheim Kg Neue Aminosäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
MY132550A (en) * 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
JP3793612B2 (ja) * 1996-11-28 2006-07-05 花王株式会社 皮膚外用剤
EP1352659A4 (fr) * 2000-12-22 2004-06-30 Takeda Chemical Industries Ltd Medicaments de combinaison
JP2003238986A (ja) * 2002-02-22 2003-08-27 Shiseido Co Ltd サブスタンスｐ増加抑制剤
ITFI20030113A1 (it) * 2003-04-24 2004-10-25 Menarini Ricerche Spa Composti lineari nk-2 antagonisti con caratteristiche basiche e formulazioni che li contengono.
JO2630B1 (en) * 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
MY177591A (en) * 2006-10-16 2020-09-22 Lion Corp Nk1 receptor antagonist composition
EP1938804A1 (fr) * 2006-12-22 2008-07-02 Novartis AG Préparation pharmaceutique comprenant un antagoniste de neurokinine
EP2175886A1 (fr) * 2007-06-28 2010-04-21 CNSBio Pty Ltd Procédés et compositions de combinaison pour le traitement d'une douleur neuropathique

Also Published As

Publication number Publication date
EP2400953A1 (fr) 2012-01-04
AU2010217615A1 (en) 2011-09-08
EA201101207A1 (ru) 2012-04-30
SG173758A1 (en) 2011-09-29
CL2011002045A1 (es) 2012-01-13
MX2011008878A (es) 2011-09-21
CN102395358A (zh) 2012-03-28
TN2011000428A1 (en) 2013-03-27
IL214731A0 (en) 2011-11-30
JP5425229B2 (ja) 2014-02-26
AU2010217615C1 (en) 2013-05-23
BRPI1008008A2 (pt) 2016-02-23
WO2010097381A1 (fr) 2010-09-02
JP2012518622A (ja) 2012-08-16
CA2753330A1 (fr) 2010-09-02
US20120077803A1 (en) 2012-03-29
TW201034674A (en) 2010-10-01
KR20110118830A (ko) 2011-11-01

Similar Documents

Publication Publication Date Title
MA33059B1 (fr) Utilisation d'antagonistes des recepteurs nk
MX338489B (es) Derivados de hidantoina utiles como inhibidores de kv3.
EA201070423A1 (ru) Диарильные соединения оксадиазолов
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
EA201070238A1 (ru) Соединения пиримидина
JO3407B1 (ar) مركبات رباعي هيدرو بيرازولو بيريميدين
EA201590748A1 (ru) Противовирусные соединения против rsv
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
UA107445C2 (uk) 5-фторпіримідинові похідні як фунгіциди
DE602007012072D1 (de) Orantagonisten
JO3515B1 (ar) مثبطات fgfr4 بيريميدين
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
BR112014013150A2 (pt) benzimidazoles e benzopirazoles substituídas como antagonistas de ccr(4)
MX2009005363A (es) Pirimidinas y su uso como antagonistas del receptor cxcr2.
EA201171210A1 (ru) Производные оксадиазола
EA201071234A1 (ru) Производные изохинолинона в качестве nk3 антагонистов
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
WO2010116282A8 (fr) Composés 4,5-dihydro-lh-pyrazole et leurs utilisations pharmaceutiques
CL2008001074A1 (es) Uso de compuestos de triazol, antagonistas de smo para tratar cancer.
EA200870515A1 (ru) Моноциклические гетероарильные соединения
MX342947B (es) Tratamiento de diabetes tipo 2.
IL206359A0 (en) Sulfonamides as orexin antagonists
IL209629A0 (en) Pyrrolidin - 3 - ylmethyl - amine as orexin antagonists
EA201170672A1 (ru) Соединения, пригодные для лечения целлюлита
SI2201002T1 (sl) Antagonisti 5-ht7 receptorja